Phase II trial

Urinary system
#Cancer treatment #China #Oncology #Phase II trial #Regulatory

Astellas’ urothelial cancer drug approved in China

China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for enfortumab vedotin for urothelial cancer. The approval is in patients with locally advanced or metastatic urothelial cancer (la/mUC) who have received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy. “In China, there were nearly 86,000… Read More

#News #Regulatory

Chronic gout
#Atom Bioscience #China #Clinical trial #Gout #hyperuricemia #Phase II trial

URAT1 inhibitor controls chronic gout at low doses

Atom Bioscience has revealed positive results from its China Phase IIa clinical trial of ABP-671, its URAT1 inhibitor for chronic gout.  The randomised, double-blind, placebo-controlled trial enrolled 54 patients with gout or  across six cohorts, with seven randomised to ABP-671 and two to placebo per cohort. … Read More

#News

Vaccine
#AELIX Therapeutics #HIV #Immune response #Immunology / Virology & Vaccines #Phase II trial #T cell activation

HIV combination regimen could lead to viral remission

AELIX Therapeutics has announced positive results from its randomised, placebo-controlled Phase IIa therapeutic HIV vaccine and immune modulator combination clinical trial.  The AELIX-003 trial evaluated the safety, tolerability, immunogenicity and efficacy of AELIX’s HTI T-cell therapeutic HIV vaccine in combination with Gilead’s investigational Toll-Like Receptor 7 (TLR7)… Read More

#News #Trending News

Doctor vaccinating baby
#FDA #Immunology / Virology & Vaccines #Paediatric #Phase II trial #Pneumonia

Pneumococcal vaccine gets go-ahead for infant trial

The US Food and Drug Administration (FDA) has cleared Vaxcyte’s infant Investigational New Drug (IND) application for VAX-24, its 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).  The company plans to initiate the infant Phase II study in the second… Read More

#News

Testing visual acuity
#Aura Biosciences #Cancer research #Melanoma #Oncology #Ophthalmology #Phase II trial

Choroidal melanoma drug preserved vision in Phase II study

Aura Biosciences has announced positive interim Phase II safety and efficacy data for belzupacap sarotalocan (bel-sar) as a first-line treatment for patients with early-stage choroidal melanoma with suprachoroidal administration.  The results showed a statistically significant reduction in tumour growth rate compared to each patient’s documented growth rate… Read More

#Cancer Research #News

Degeneration of dopaminergic neuron
#Clinical trial #Neurology #Neuroscience #Newron Pharmaceuticals #Phase II trial #Schizophrenia

Evenamide could ‘open new treatment pathways’ for TRS

Newron Pharmaceuticals’ Evenamide could be a potential breakthrough treatment in the management of treatment-resistant schizophrenia (TRS) patients, according to new trial data.  The drug is being assessed as an add-on to an antipsychotic (excluding clozapine) in patients with moderate to severe TRS who are not responding to… Read More

#Editor's Choice #News

MRI of the brain
#Clinical trial #Minoryx Therapeutics #Neurodegenerative disorders #Phase II trial

New treatment slows progression of neurodegenerative disease

Minoryx Therapeutics has revealed the findings from the first and largest international study to enroll adult male X-linked adrenoleukodystrophy patients.  The Phase II/III ADVANCE clinical trial of lead candidate, leriglitazone, published in The Lancet Neurology, did not meet the primary outcome… Read More

#News #Trending News

Hepatitis B
#hepatitis #Immunology / Virology & Vaccines #Immunotherapy #Phase II trial #siRNA #VBI Vaccines

Hepatitis B combination restores antibody and T cell responses

Biopharmaceutical company VBI Vaccines has revealed interim data from its Phase II study evaluating the combination of VBI-2601, VBI’s HBV immunotherapeutic candidate, and BRII-835, an HBV-targeting siRNA candidate, in chronically infected hepatitis B (HBV) patients.   The data demonstrate that the combination therapy was generally well-tolerated, restored strong… Read More

#News #Trending News

Patient having a mammogram
#Breast cancer #Cancer research #Clinical research #Clinical trials #Oncology #Phase II trial

Breast cancer still top disease area for clinical studies

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi.  The company’s global analysis of all clinical trials conducted in 2022 showed that Covid-19 came second.   Three of… Read More

#Cancer Research #News

Non-small cell lung cancer
#Biomarkers #Lung cancer #Merck #Oncology #Phase II trial #Precision medicine #Regulatory #Scottish Medicines Consortium (SMC)

SMC approves targeted treatment for lung cancer

Following a resubmission from manufacturer Merck, the Scottish Medicines Consortium (SMC) has now approved Tepmetko (tepotinib) for use on the NHS in Scotland.   It is recommended for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring mesenchymal-epithelial transition factor gene (MET) exon 14 (METex14) skipping alterations.  … Read More

#News #Regulatory

#Cancer research #Clinical trials #Drug development #Drug discovery #Phase I trial #Phase II trial #Phase III trial

DDW Highlights podcast: 23 January 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  Clinical trials have led our news section this week, with positive results… Read More

#News

#Cancer research #Clinical trials #Drug development #Drug discovery #Phase I trial #Phase II trial #Phase III trial

This week in drug discovery (16-20 January)

News round-up for 19-20 January by DDW Digital Content Editor Diana Spencer. Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not… Read More

#News

Identifying bacteria in the lab
#Abionyx Pharma #Gram-negative bacteria #Kidney disease #Phase II trial #Sepsis

New drug reduced renal damage in septic patients

A pilot Phase IIa clinical trial evaluating Abionyx Pharma’s CER-001 as a treatment for septic patients at high risk of developing acute kidney injury (AKI) has met its primary endpoint.  The RACERS study included 20 patients with gram-negative sepsis who were at high risk for acute kidney… Read More

#Editor's Choice #News

Patient speaking to psychiatrist
#Alta Neuroscience #Biomarkers #Major depressive disorder #Neuroscience #Phase II trial #Precision psychiatry #Psychiatry

Precision drug could redefine depression treatment

A Phase IIa study of Alto Neuroscience’s ALTO-100 has demonstrated clear evidence of efficacy and a favourable safety record in patients with major depressive disorder (MDD).   In the study, patients with a biomarker profile that ties back to a mechanistic understanding of ALTO-100 and depression exhibited a… Read More

#News

Patients receiving chemotherapy
#Cancer treatment #Chemotherapy #Hearing Loss #Phase II trial #Sensorion

Drug could prevent chemotherapy-induced hearing loss

Biotechnology company Sensorion has enrolled the first patient in its Phase IIa Proof of Concept clinical trial of SENS-401 (Arazasetron) in patients suffering from cisplatin-induced ototoxicity.  Cisplatin and other platinum-based compounds are essential chemotherapeutic agents for many cancers. A serious side effect of these therapies is ototoxicity,… Read More

#Cancer Research #News

Nasal spray
#Beckley Psytech #Depression #Phase II trial #Psychiatry #Treatment-resistant depression

Phase IIa study begins in treatment resistant depression

Beckley Psytech has initiated a Phase IIa study investigating BPL-003, a proprietary intranasal formulation of synthetic 5-Methoxy-N, N-Dimethyltryptamine (5-MeO-DMT), for treatment resistant depression (TRD).  Depression affects around 280 million people around the world, but 30% of those living with the condition are resistant to available antidepressant medications,… Read More

#News